Please upgrade your browser.
Glyn Edwards, CEO of Antisoma, said: "We're delighted to share a wealth of new data on AS1413 and AS1411 at the ASCO meeting. Both drugs are approaching important milestones, with phase III data on AS1413 and phase IIb data on AS1411 due in the next 12 months. The latest findings provide further evidence of the unique potential of these novel approaches to cancer therapy."
Abstracts published in the Annual Meeting Proceedings: late-Breaking Abstracts, and Clinical Review Abstracts will be available at 12:00 PM EDT on the date of their presentation at the 2010 ASCO Annual Meeting.
Genomic Health Announces Results From the Largest Genomic Analysis of Localized Clear Cell Renal Carcinoma at American Society of Clinical Oncology (ASCO) Annual Meeting
First Publically Presented Results of Industry-Leading Collaboration Aimed to Assess Prognosis for Early-Stage Renal Cell Carcinoma.
Abbott to Present Data on Several Investigational Cancer Treatments at American Society of Clinical Oncology Annual Meeting
Abbott data being presented includes two oral presentations on elotuzumab, an antibody designed to bind to the CS1 glycoprotein, a highly expressed cell surface protein in multiple myeloma. Four separate studies of linifanib (ABT-869), which is being studied as an inhibitor of the VEGFR and PDGFR kinase pathways, in advanced renal cell cancer (RCC), advanced solid tumors, advanced hepatocellular carcinoma (HCC) and non small cell lung cancer (NSCLC), also will be presented.
A detailed analysis of the epigenetics -- factors controlling when and in what tissues genes are expressed -- of Wilms tumor reveals striking similarities to stem cells normally found in fetal kidneys.
Newly discovered markers cannot increase patient survival, rather their prognostic value supporting therapeutic decisions or new agents targeted at these new markers.
Small but decisive study highlights differences in clear- and non-clear cell subtypes.
Prometheus to Present New Data on Proprietary Oncology Diagnostic Platform at ASCO Annual Meeting Read more: Prometheus to Present New Data on Proprietary Oncology Diagnostic Platform at ASCO Annual
Data will also be presented from independent studies of PROLEUKIN® (aldesleukin), a recombinant human interleukin-2 for treatment in adults with metastatic melanoma and metastatic renal cell carcinoma.
|Powered by NeonCRM|